Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Meeting report: antisense oligonucleotides

G Martinelli1, S Ferrari

  • 1Istituto di Ematologia L.e A. Seràgnoli, Università di Bologna, Italy.

Haematologica
|March 1, 1994
PubMed
Summary
This summary is machine-generated.

Antisense oligonucleotides offer a novel therapeutic strategy for disease by selectively inhibiting gene expression. This approach has shown promise in targeting genes like bcl-2, c-myb, and P53 in various cell types.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups.

Blood cancer journal·2013
Same author

Filgrastim XM02 (Tevagrastim®) after autologous stem cell transplantation compared to lenograstim: favourable cost-efficacy analysis.

Ecancermedicalscience·2013
Same author

Experimental demonstration of modulation instability in an optical fiber with a periodic dispersion landscape.

Optics letters·2012
Same author

Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance.

Leukemia·2012
Same author

BCR-ABL-specific cytotoxic T cells in the bone marrow of patients with Ph(+) acute lymphoblastic leukemia during second-generation tyrosine-kinase inhibitor therapy.

Blood cancer journal·2012
Same author

Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia.

Blood cancer journal·2012
Same journal

Emapalumab and eltrombopag rescue for prolonged immune effector cell-associated hemophagocytic syndrome after CAR T-cell therapy in multiple myeloma.

Haematologica·2026
Same journal

Incidence and predictors of recurrent venous thromboembolism after isolated distal deep vein thrombosis: a <i>post-hoc</i> analysis of the RIDTS trial.

Haematologica·2026
Same journal

Philadelphia positive T-acute lymphoblastic leukemia: a Mayo Clinic series.

Haematologica·2026
Same journal

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Haematologica·2026
Same journal

Reframing leukemia-niche interactions: the emerging role of the marrow adipocyte lineage.

Haematologica·2026
Same journal

A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma.

Haematologica·2026
See all related articles

Area of Science:

  • Molecular Biology
  • Gene Therapy
  • Hematology

Background:

  • Antisense oligonucleotides represent a new therapeutic strategy for modulating gene expression.
  • These molecules can be designed to hybridize with specific gene or messenger RNA sequences, blocking transcription or translation.
  • This technology holds potential for treating various diseases by targeting specific genetic pathways.